Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Rhea-AI Summary

Nektar (Nasdaq:NKTR) will announce its third-quarter 2025 financial results on Thursday, November 6, 2025 after the U.S. market close. Howard Robin, President and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT to review results. A press release and an audio-only webcast link will be posted on the company's investor relations site at https://ir.nektar.com/. The web broadcast replay will be available through December 6, 2025. Investors must pre-register to receive dial-in details and a PIN to access the live call.

SAN FRANCISCO, Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through December 6, 2025.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call. 

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts:

For Investors:

Vivian Wu
VWu@nektar.com

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com 
212-915-2577

Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com 
212-915-3820

For Media:

Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-on-thursday-november-6-2025-after-close-of-us-based-financial-markets-302597142.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar (NKTR) report third-quarter 2025 results?

Nektar will report Q3 2025 results on November 6, 2025 after U.S. markets close.

What time is the Nektar (NKTR) Q3 2025 conference call and who is hosting?

The call is at 5:00 p.m. ET / 2:00 p.m. PT on November 6, 2025, hosted by CEO Howard Robin.

How can investors access the Nektar (NKTR) earnings webcast and replay?

Access the audio-only webcast via https://ir.nektar.com/; the replay is available through December 6, 2025.

Do I need to register to join the Nektar (NKTR) November 6 earnings call?

Yes. Pre-register at the Nektar earnings call registration page to receive dial-in information and a PIN.

Where will Nektar (NKTR) publish its Q3 2025 press release and supplemental materials?

The press release and any materials will be posted on the company's Home Page and Investors section at https://ir.nektar.com/.